Onconetix Reports 67.7% Revenue Decline, Focuses on Proclarix Commercialization

Onconetix, Inc., a biotechnology company focused on men's health and oncology, reported a significant decline in revenue for the fiscal year ended December 31, 2025, with total revenue of $815,371, down 67.7% from $2.5 million in 2024. This decrease was primarily attributed to the completion of a service contract with Immunovia in 2024, which did not recur in 2025. The company also noted a reduction in development services revenue, which fell by $2.3 million. Despite this, Onconetix's gross profit was $632,913, reflecting a positive gross margin, although the overall financial performance was impacted by substantial operating expenses.

Total operating expenses decreased by 67.9% to $18.5 million in 2025, compared to $57.5 million in the previous year. This reduction was largely due to cost-cutting measures, including a decrease in payroll-related expenses and the termination of the defined benefit plan. Notably, the company recorded an impairment of goodwill related to the acquisition of Proteomedix, totaling $11.5 million, which contributed to a net loss of $14 million for the year, a significant improvement from the $58.7 million loss reported in 2024.

Onconetix's strategic focus has shifted towards the commercialization of Proclarix, an in vitro diagnostic test for prostate cancer, following the abandonment of its ENTADFI product due to resource constraints. The company has entered into a licensing agreement with LabCorp for the development and commercialization of Proclarix in the U.S., which is expected to generate revenue in the future. The company anticipates that sales from Proclarix will help offset some operational expenses, although it continues to face challenges in achieving sustained positive cash flows.

The company has also engaged in significant financing activities, including Series D and E PIPE financings, which provided approximately $14.5 million in cash flow to support operations. However, as of December 31, 2025, Onconetix reported a working capital deficit of approximately $3.1 million and an accumulated deficit of $131.2 million, raising substantial doubt about its ability to continue as a going concern. Management plans to pursue additional equity or debt financing to support ongoing operations and strategic initiatives.

Looking ahead, Onconetix is focused on the successful commercialization of Proclarix and the potential for future product candidates. The company is also navigating the complexities of regulatory approvals and market acceptance, which are critical for its growth. The recent acquisition of Realbotix Corp. is expected to enhance its product offerings, although the integration of the two businesses poses additional challenges. Overall, Onconetix's future performance will depend on its ability to effectively manage its resources, navigate regulatory landscapes, and achieve market acceptance for its diagnostic solutions.